Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2014-03-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-014-2422-zPMID 24619496
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.

  2014cited by this paper
• The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma

  2012cited by this paper
• CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

  2012cited by this paper
• CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

  2012cited by this paper
• Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma

  2012cited by this paper
• Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series

  2011cited by this paper
• Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.

  2011cited by this paper
• Medical treatment of recurrent meningiomas

  2011cited by this paper
• Treatment of unresectable skull base meningiomas with somatostatin analogs.

  2011cited by this paper
• Central nervous system cancers.

  2011cited by this paper
• Pathological classification and molecular genetics of meningiomas

  2010cited by this paper
• Medical therapies for meningiomas

  2010cited by this paper
• Management of meningiomas.

  2010cited by this paper
• Epidemiology and etiology of meningioma

  2010cited by this paper
• Interferon‐α for recurrent World Health Organization grade 1 intracranial meningiomas

  2008cited by this paper
• Meningioma.

  2008cited by this paper
• Antitumor effects of somatostatin.

  2008cited by this paper
• Recurrent meningioma

  2007cited by this paper
• Ki‐67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma

  2007cited by this paper
• Central nervous system cancers: Clinical Practice Guidelines in Oncology.

  2005cited by this paper
• Epidemiology of intracranial meningioma.

  2005cited by this paper
• Expression of Somatostatin Receptor mRNA in Human Meningiomas and their Implication in in vitro Antiproliferative Activity

  2004cited by this paper
• Non-Resectable Slow-Growing Meningiomas Treated by Hydroxyurea

  2004cited by this paper
• Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.

  2003cited by this paper
• Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A.

  2000cited by this paper
• Visual improvement during octreotide therapy in a case of episellar meningioma.

  1998cited by this paper
• Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.

  1997cited by this paper
• Somatostatin analogs: future directions.

  1996cited by this paper
• Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2.

  1994cited by this paper
• Clinical use of octreotide in unresectable meningiomas. A report of three cases.

  1993cited by this paper
• A Report of Three Cases

  1986cited by this paper

• Meningioma: Novel Diagnostic and Therapeutic Approaches

  2025cites this paper
• Benchmarking the Efficacy of Salvage Systemic Therapies for Recurrent Meningioma: A RANO Group Systematic Review and Meta-analysis to Guide Clinical Trial Design.

  2025cites this paper
• Diagnostic advances and challenges in meningioma

  2025cites this paper
• The concept, intention, and evaluation of the term treatment-refractory meningioma

  2025cites this paper
• Recurrent TRAF7-mutated meningioma: Molecular evolution and therapeutic insights

  2025cites this paper
• A Case of Acromegaly With Parasellar Meningioma With Oculomotor Palsy Responding to and Maintained With Oral Octreotide Therapy

  2025cites this paper
• Radioligand therapies in meningioma: Evidence and future directions

  2024cites this paper
• Management Approaches in WHO Grade III Meningioma: A National Oncology Trainees' Collaborative for Healthcare Research (NOTCH) UK Multi-Centre Retrospective Study.

  2024cites this paper
• Noncoding RNA landscape and their emerging roles as biomarkers and therapeutic targets in meningioma

  2024cites this paper
• Cytotoxicity on low-grade canine meningioma with the use of somatostatin analog (octreotide): An in vitro study

  2024cites this paper
• Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients

  2024cites this paper
• Meningiomas and Somatostatin Analogs: A Systematic Scoping Review on Current Insights and Future Perspectives

  2023cites this paper
• Signaling pathways in brain tumors and therapeutic interventions

  2023cites this paper
• The Role of Pharmacotherapy in Treatment of Meningioma: A Systematic Review

  2023cites this paper
• Somatostatin and Somatostatin Receptors in Tumour Biology

  2023cites this paper
• Advances in the systemic therapy for recurrent meningiomas and the challenges ahead

  2023cites this paper
• Meningioma and Other Meningeal Tumors.

  2023cites this paper
• Medical Management of Meningiomas.

  2023cites this paper
• Diagnostic and Therapeutic Strategy in Anaplastic (Malignant) Meningioma, CNS WHO Grade 3

  2022cites this paper
• How useful is chemotherapy for atypical and anaplastic meningiomas?

  2022cites this paper
• Emerging systemic treatment options in meningioma

  2022cites this paper
• The role of bevacizumab for treatment-refractory intracranial meningiomas: a single institution’s experience and a systematic review of the literature

  2022cites this paper
• Management of Recurrent Meningiomas: State of the Art and Perspectives

  2022cites this paper
• Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data

  2022cites this paper
• Molecular determinants of outcomes in meningiomas

  2022cites this paper
• Advances in Molecular Biological and Translational Studies in World Health Organization Grades 2 and 3 Meningiomas: A Literature Review

  2022cites this paper
• Clinical Significance of Molecular Alterations and Systemic Therapy for Meningiomas: Where Do We Stand?

  2022cites this paper
• Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort

  2021cites this paper
• Preparation of Long-acting Somatostatin and GnRH Analogues and their Applications in Tumor Therapy.

  2021cites this paper
• 10 Management of Benign Skull Base Tumors in Neuro-oncology: Systemic Cytotoxic and Targeted Therapies Systemic cytotoxic and targeted therapies Benign skull base tumors in neuro-oncology

  2021cites this paper
• Advances in Multidisciplinary Management of Skull Base Meningiomas

  2021cites this paper
• Systemic Treatments for Grade II and III Meningiomas (WHO)

  2021cites this paper
• Chemotherapy and targeted therapies for meningiomas: what is the evidence?

  2021cites this paper
• Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas

  2021cites this paper
• Perisellar solid tumors

  2021cites this paper
• Brain-invasive meningiomas: molecular mechanisms and potential therapeutic options

  2021cites this paper
• A narrative review of targeted therapies in meningioma.

  2020cites this paper
• Recent Advances in Meningioma Immunogenetics

  2020cites this paper
• Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial

  2020cites this paper
• Children’s Cancer and Leukaemia Group (CCLG): review and guidelines for the management of meningioma in children, teenagers and young adults

  2020cites this paper
• A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas

  2020cites this paper
• Meningioma: Signaling pathways and tumor growth.

  2020cites this paper
• Medical management of meningiomas.

  2020cites this paper
• A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base.

  2020cites this paper
• Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma

  2020cites this paper
• Review of Atypical and Anaplastic Meningiomas: Classification, Molecular Biology, and Management

  2020cites this paper
• Meningiomas: Comprehensive Strategies for Management

  2020cites this paper
• The Role of Medical Therapy for Menigniomas

  2020cites this paper
• Grade III meningioma with gastro-intestinal tract and brain metastases: case report and review of the literature

  2019cites this paper
• Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome

  2019cites this paper
• Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib

  2019cites this paper
• Initial management of meningiomas: Analysis of the National Cancer Database.

  2019cites this paper
• Multimodality Therapy of Patients with Refractory Meningiomas

  2019cites this paper
• A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR(octreotide) for Treatment of Recurrent and/or Refractory Meningiomas

  2019cites this paper
• Medical management of meningioma in the era of precision medicine.

  2018cites this paper
• New molecular targets in meningiomas: the present and the future

  2018cites this paper
• Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?

  2018cites this paper
• T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection

  2018cites this paper
• An overview of meningiomas.

  2018cites this paper
• PD-L1 expression in meningiomas.

  2018cites this paper
• Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design

  2018cites this paper
• Value of SSTR2A and Claudin - 1 in Differentiating Meningioma from Schwannoma and Hemangiopericytoma

  2018cites this paper
• Tumors of the Central Nervous System

  2018cites this paper
• Meningiomas: Overview and New Directions in Therapy

  2018cites this paper
• Predictors of Treatment Response and Survival Outcomes in Meningioma Recurrence with Atypical or Anaplastic Histology

  2018cites this paper
• Transforming Growth Factor Beta Family in the Pathogenesis of Meningiomas.

  2017cites this paper
• Brain Tumors—Epidemiology

  2017cites this paper
• Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs.

  2017cites this paper
• Longitudinal experience with WHO Grade III (anaplastic) meningiomas at a single institution

  2017cites this paper
• Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review.

  2017cites this paper
• Case-Based Review: meningioma.

  2016cites this paper
• Osobitosti ekstracerebralnih tumora lubanjskog svoda

  2016cites this paper
• Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons.

  2016cites this paper
• Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.

  2016cites this paper
• Microsurgical management of primary jugular foramen meningiomas: a series of 22 cases and review of the literature

  2016cites this paper
• Systemic therapy for recurrent meningioma

  2016influential citation
• Drug Resistance in Malignant Meningiomas

  2016cites this paper
• Unresectable Recurrent Multiple Meningioma: A Case Report with Radiological Response to Somatostatin Analogues

  2016cites this paper
• RECURRENT MENINGIOMA AFTER INITIAL RESECTION SURGERY – CASE REPORT

  2015cites this paper
• World Health Organization grade III meningiomas. A retrospective study for outcome and prognostic factors assessment

  2015cites this paper
• Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma

  2015cites this paper
• Systemic Treatment of Recurrent Meningioma

  2013cites this paper
• World Journal of Experimental Medicine

  year unknowncites this paper
• Usage and Distribution for Commercial Purposes Requires Written Permission. Unresectable Recurrent Multiple Meningioma: a Case Report with Radiological Response to Somatostatin Analogues Ortolá Buigues Et Al.: Unresectable Recurrent Multiple Meningioma: a Case Report with Radiological Response to So

  year unknowncites this paper